Full Version | Search

The Irish Medicines Board - www.imb.ie

IMB Logo

XGEVA (denosumab) - Important Safety Information from Amgen as approved by the Irish Medicines Board

04 September 2012

Important Safety Information communication from Amgen on the risk of severe symptomatic hypocalcaemia associated with the use of denosumab and the risk of late onset of hypocalcaemia.

Important Safety Information - XGEVA (denosumab)





Date Printed: 21 May 2013

© Irish Medicines Board 2013 | Developed by Engine Solutions www.engine.ie

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971